Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma
Open Access
- 29 April 2003
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (9) , 1346-1351
- https://doi.org/10.1038/sj.bjc.6600915
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell CancerNew England Journal of Medicine, 2001
- Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialThe Lancet, 2001
- Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2001
- Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon ? in the treatment of metastatic renal cell carcinoma: a pilot studyCancer Immunology, Immunotherapy, 2001
- Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2000
- Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 1998
- Anti-tumoral effect of GM-CSF with or without cytokines and monoclonal antibodies in solid tumorsMedical Oncology, 1996
- Prognostic Factors for Survival in Patients with Metastatic Renal Cancer Treated with Biological Response ModifiersJournal of Urology, 1995
- Immunologic Effects of InterferonJournal of Investigative Dermatology, 1990